Constitutively active ALK2 receptor mutants require type II receptor cooperation

Jana Bagarova1, Ashley J Vonner, Kelli A Armstrong

  • 1Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Insights

Constitutively active mutant ALK2 receptors driving fibrodysplasia ossificans progressiva (FOP) require type II receptors for signaling. This interaction is independent of ligand binding or kinase activity, highlighting a nonenzymatic scaffolding role for therapeutic insights.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Developmental Biology

Background:

  • Activating mutations in receptor kinases, like ACVR1 in fibrodysplasia ossificans progressiva (FOP), lead to aberrant signaling and disease.
  • The precise mechanism by which constitutively active ALK2 mutants (caALK2) signal, particularly their dependence on type II receptors and ligands, remains unclear.

Purpose of the Study:

  • To investigate whether constitutively active ALK2 receptors can signal independently of type II receptors and ligands.
  • To define the minimal requirements for caALK2 signaling and its role in heterotopic ossification.

Main Methods:

  • Utilized cell-based assays and mouse models with genetic ablation of BMP type II receptors (BmpRII and ActRIIa).
  • Assessed signaling, transcription, and heterotopic ossification phenotypes.

Main Results:

  • Ablation of BmpRII and ActRIIa abrogated both BMP ligand-mediated and caALK2-mediated signaling and transcription.
  • caALK2-induced heterotopic ossification in mice was disrupted upon type II receptor ablation.
  • Signaling by GS domain ALK2 mutants could be restored by expressing either BMP type II receptor, independent of ligand binding or kinase activity, but dependent on the cytoplasmic domain.

Conclusions:

  • Constitutively active ALK2 mutants signal independently of upstream pathways but require a nonenzymatic scaffolding function from type II receptors.
  • Type II receptors are essential for forming functional, potentially ligand-independent signaling complexes with caALK2.
  • These findings provide critical insights into the minimal requirements for caALK2 signaling, informing therapeutic strategies for FOP and related conditions.

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.